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Selective serotonin reuptake inhibitors (SSRIs) help
treat many of the phenotypic manifestations of fragile X
syndrome (FXS) including anxiety, sensory processing
challenges, and communication and intellectual deficits.
However, the efficacy of SSRIs has not been previously
studied in children with FXS under five-years-old. The
purpose of this study was to elucidate group differences
in behavior and developmental outcome measures for





• This is the first known controlled trial of sertraline in
young children with FXS.
• No significant differences were observed in the
MSEL expressive language subscales and CGI-I
primary outcome measures for sertraline when
compared to placebo.
• Secondary measures revealed significant
improvement in social participation on the SPM-P.
Areas of fine motor and visual perception were also
significantly improved on the MSEL when compared
to age equivalent subjects. Post hoc analysis
combining all MSEL age-equivalent scores
(expressive, visual, receptive and fine motor) showed
overall significant improvement.
• Results suggest sertraline had significant positive
effect on social improvements and overall
development.
• Adverse events (AEs) were similar between
sertraline and placebo groups. No significant
differences in characteristics of AEs were observed
between both groups.
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• 57 participants with FXS, ages 2 -6 years old (mean
3.9 years; SD 1.1)
• Randomized, 6-month, double-blind, placebo-
controlled trial of sertraline (Zoloft)
• Baseline and post-treatment outcomes measured
• Primary outcomes: Mullen Scales of Early Learning
(MSEL) expressive language subscales and Clinical
Global Impression Scale-Improvement (CGI-I)
• Secondary outcomes: MSEL fine motor, visual
reception, and receptive language subscales; Autism
Diagnostic Observation Schedule, Second Ed.
(ADOS-2); Visual Analog Scale (VAS); Sensory
Processing Measure-Preschool (SPM-P); and


































81 subjects assessed 
for eligibility
24 subjects excluded
 12 did not meet criteria
 12 declined to participate
25 analyzed
Excluded from analysis 
(n=0)
2 discontinued treatment:
 1 lost to follow up
 1 withdrew consent







 1 lost to follow up
 2 withdrew consent
27 analyzed 






Baseline Follow Up Baseline Follow Up




Score 26 21.3 10.3 25 25.0 10.8 30 19.3 9.7 27 21.3 9.6 0.586
Exp Lang
T‐Score 27 25.8 11.7 25 25.8 10.9 30 23.3 5.8 27 22.6 6.5 0.607
CGI‐I 27 ‐‐ ‐‐ 25 2.3 1.1 30 ‐‐ ‐‐ 27 2.6 0.8 0.244
















































Variable No. of Patients % No. of Patients % P‐value
Severity
No Moderate/Severe AE 12 46.15 15 51.72 0.7891
Any Moderate/Severe AE 14 53.85 14 48.28
Drug Related
No drug related AE 5 19.23 6 20.69 1
Any drug related AE 21 80.77 23 79.31
Serious Adverse Event
No 26 100 29 100 ‐‐
Adverse Event Status
No Ongoing 21 26 80.77 89.66 0.4548
Any Ongoing 5 3 19.23 10.34
Comparison of Adverse Events
